Status:
COMPLETED
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2
Lead Sponsor:
Daewon Pharmaceutical Co., Ltd.
Conditions:
Osteoarthritis
Rheumatoid Arthritis
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study
Eligibility Criteria
Inclusion
- Healthy Volunteers who are ≥19 years old
- Body weight ≥50.0 kg and BMI between 18.0 and 30.0 kg/m2 and
Exclusion
- Clinically significant Medical History
- In the case of women, pregnant(Urine-HCG positive) or lactating women
Key Trial Info
Start Date :
August 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 8 2020
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT05214690
Start Date
August 13 2020
End Date
September 8 2020
Last Update
January 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chungbuk National University Hospital
Cheongju-si, South Korea